Amgen (AMGN): Kyprolis Fails to Show PFS Benefit - BMO
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
BMO Capital analyst, Ian Somaiya, reiterated his Outperform rating on shares of Amgen (NASDAQ: AMGN) after Kyprolis failed to show a PFS benefit versus Velcade in front-line myeloma.
These results do not impact the analyst's estimates but they do eliminate ~ $1.5bn in potential upside.
Kyprolis now faces increased risk from generic Velcade as positive data could reduce pressure from payors to switch to generic. The majority of impact will be in Europe as melphalan/prednisone regimens have limited (<5%) US use.
No change to the price target of $190.
Shares of Amgen closed at $173.53 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Cuts Price Target on Cooper Cos. (COO) Following 4Q Results
- UBS Raises Price Target on Selecta Biosciences (SELB) to $29
- MKM Partners Raises Price Target on Hartford Financial (HIG) to $55
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesBMO Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!